Accessibility Menu
Neurotech International logo

Neurotech International(ASX) NTI

Market CapA$21.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-95%
5 Year-69%
1 Year-13%
1 Month-13%
A$0.01
+0.00%
+0.00Today
Neurotech International last closing stock price
MetricPriceDate
Last closeAUD 0.012026-09-08
Neurotech International stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 0.012026-09-01
1 month-13.33%AUD 0.022026-08-07
3 month+8.33%AUD 0.012026-06-10
Year to date-7.14%AUD 0.012025-12-31
1 year-13.33%AUD 0.022025-09-08
3 year-74.51%AUD 0.052023-09-08
5 year-69.05%AUD 0.042021-09-09
Since inception-95.09%AUD 0.262016-11-04

Neurotech International Financials at a Glance

Market Cap

A$21.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$2.44M

Net Income (TTM)

-A$17.14M

EPS (TTM)

-A$0.01

P/E Ratio

-2.55

Dividend

A$0.00

Beta (Volatility)

0.00 (Low)

Price

A$0.01

Volume

4,458,918

Open

A$0.01

Previous Close

A$0.01

Daily Range

A$0.01 - A$0.01

52-Week Range

A$0.01 - A$0.03

Estimated Earnings Date

Mar 2, 2027

NTI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Neurotech International

Neurotech International Limited is an Australian biotechnology company focused on the research, development, and manufacturing of innovative medical devices and solutions. The company specializes in advancing its Mente platform, which is designed to facilitate home-based therapies, particularly for autism spectrum disorder.

Products and Services
  • Mente platform for home-based therapy monitoring
  • Mente Autism product for autism diagnosis and treatment
  • Various medical research projects and technological instruments
Growth Outlook
  • Expansion of the Mente platform is expected to drive future revenue growth
  • Increased focus on autism treatment aligns with rising global demand
  • Strategic partnerships may enhance research capabilities and market reach
Financial Highlights
  • Recent quarterly revenue of AUD 2,330,660 indicates potential for recovery
  • Cash and cash equivalents increased to AUD 6,326,734, providing operational stability
  • Current ratio of 7.30 suggests strong liquidity position
Neurotech International Limited operates in a niche market with significant growth potential, particularly in the field of autism treatment. The Mente platform represents a unique offering that addresses a critical need in healthcare. Recent financial data shows a positive trend in cash reserves, which can support ongoing research and development efforts. The company's focus on innovative solutions positions it well to capitalize on the growing demand for effective autism therapies. With a strong liquidity position and a commitment to advancing its technology, Neurotech International Limited presents an intriguing opportunity for investors interested in the biotechnology sector.
AI Generated • Aug 21, 2026

Industry

Healthcare Equipment and Supplies

CEO

Anthony Filippis, PhD, MBA

Headquarters

Melbourne, VI 3000, AU

NTI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-201.54%

Return on Capital

-1854.26%

Return on Assets

-237.99%

Earnings Yield

-39.22%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$21.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.62B

Volume

4.46M

Avg. Volume

2.32M

Financials (TTM)

Gross Profit

A$2.44M

Operating Income

-A$22.42M

EBITDA

-A$22.07M

Operating Cash Flow

-A$12.79M

Capital Expenditure

-A$8.00

Free Cash Flow

-A$12.79M

Cash & ST Invst.

A$2.39M

Total Debt

A$0.00

Neurotech International Performance Analysis

Neurotech International annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 5,959-84.4%
20242024-06-30AUD 1,963-67.1%
20252025-06-30AUD 238-87.9%
20262026-06-30AUD 0N/A
Neurotech International sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31442.1%
Q42025-06-301949.5%
Q22025-12-31-100.0%
Q42026-06-30N/A
Neurotech International annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.01104.2%
20242024-06-30AUD -0.01-42.9%
20252025-06-30AUD -0.0182.1%
20262026-06-30AUD -0.01-46.1%
Neurotech International sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-58.7%
Q42025-06-3058.9%
Q22025-12-31100.0%
Q42026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

+100.0%

Gross Profit

A$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

A$21.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.17M

N/A

Employees

18

N/A

Net Income

-A$5.84M

-34.6%

EBITDA

-A$5.91M

-31.3%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$2.39M

-79.5%

Total Debt

A$0.00

N/A

Accounts Receivable

A$342.34K

+7.6%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-2.38%

N/A

Return on Invested Capital

-18.54%

N/A

Free Cash Flow

-A$38.33K

+95.6%

Operating Cash Flow

-A$38.33K

+95.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BTC.AXBTC Health Limited
A$0.06+0.00%
AGH.AXAlthea Group Holdings Limited
A$0.02-4.76%
AT1.AXAtomo Diagnostics Limited
A$0.02+0.00%
MDR.AXMedAdvisor Limited
A$0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$100.83+0.05%
NVDANvidia
$228.85-0.01%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$44.27-0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.48+0.04%

Questions About NTI

What is the current price of Neurotech International?

Neurotech International is trading at A$0.01 per share.

What is the 52-week range for Neurotech International?

Over the past 52 weeks, Neurotech International has traded between A$0.01 and A$0.03.

How much debt does Neurotech International have?

As of the most recent reporting period, Neurotech International reported total debt of A$0.00.

How much cash does Neurotech International have on hand?

Neurotech International reported A$2.39M in cash and cash equivalents in its most recent financial results.

What is Neurotech International’s dividend yield?

Neurotech International does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.